FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
DE69533295T3
(de)
*
|
1994-02-16 |
2009-07-16 |
The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services |
Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
|
US20020031493A1
(en)
*
|
1994-03-25 |
2002-03-14 |
Rhone-Poulenc Rorer S.A. |
Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
|
US7252989B1
(en)
*
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
DE69535178T2
(de)
*
|
1994-06-10 |
2006-12-14 |
Genvec, Inc. |
Adenoviren-vektor systeme und zelllinien
|
EP0707071B1
(de)
*
|
1994-08-16 |
2003-07-30 |
Crucell Holland B.V. |
Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
|
DK0787200T3
(da)
*
|
1994-10-28 |
2005-08-15 |
Univ Pennsylvania |
Forbedret adenovirus og fremgangsmåder til anvendelse heraf
|
AU709498B2
(en)
*
|
1994-12-12 |
1999-09-02 |
Genetic Therapy, Inc. |
Improved adenoviral vectors and producer cells
|
US20030148968A1
(en)
*
|
1995-02-28 |
2003-08-07 |
Hammond H. Kirk |
Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
|
JP3961019B2
(ja)
|
1995-02-28 |
2007-08-15 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
遺伝子転移媒介の血管形成療法
|
JP3770333B2
(ja)
*
|
1995-03-15 |
2006-04-26 |
大日本住友製薬株式会社 |
組換えdnaウイルスおよびその製造方法
|
CA2218610A1
(en)
*
|
1995-04-17 |
1996-10-24 |
Board Of Regents, The University Of Texas System |
An adenovirus helper-virus system
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6783980B2
(en)
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
ES2333425T5
(es)
|
1995-06-15 |
2012-08-28 |
Crucell Holland B.V. |
Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
|
AU722042B2
(en)
*
|
1995-11-30 |
2000-07-20 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the diagnosis and treatment of cancer
|
AU1695197A
(en)
*
|
1996-01-05 |
1997-08-01 |
Genetic Therapy, Inc. |
Recombinase-mediated generation of adenoviral vectors
|
US6132989A
(en)
*
|
1996-06-03 |
2000-10-17 |
University Of Washington |
Methods and compositions for enhanced stability of non-adenoviral DNA
|
US6730662B1
(en)
*
|
1996-07-05 |
2004-05-04 |
Mcgill University |
Adenovirus E4 proteins for inducing cell death
|
US20040156861A1
(en)
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
CA2266342C
(en)
*
|
1996-09-25 |
2010-06-08 |
Novartis Ag |
Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
|
US7232899B2
(en)
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
CA2283253A1
(en)
*
|
1997-03-04 |
1998-09-11 |
Baxter International Inc. |
Adenovirus e1-complementing cell lines
|
US5849561A
(en)
*
|
1997-05-22 |
1998-12-15 |
Cornell Research Foundation, Inc. |
Method for the production of non-group C adenoviral vectors
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
CA2995542A1
(en)
|
1997-09-05 |
1999-03-11 |
Genzyme Corporation |
Methods for generating high titer helper-free preparations of recombinant aav vectors
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6995006B2
(en)
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
CA2308606A1
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
AU1979599A
(en)
|
1998-01-14 |
1999-08-02 |
Chiron S.P.A. |
(neisseria meningitidis) antigens
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
BR9910089A
(pt)
|
1998-05-01 |
2004-06-08 |
Chiron Corp |
Composições e antìgenos de neisseria meningitidis
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
US6113913A
(en)
|
1998-06-26 |
2000-09-05 |
Genvec, Inc. |
Recombinant adenovirus
|
CN1342206A
(zh)
|
1998-08-28 |
2002-03-27 |
杜克大学 |
在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
|
EP2942393A1
(de)
|
1998-09-04 |
2015-11-11 |
Genzyme Corporation |
Verfahren zur erzeugung helferfreier präparate mit hohem titer aus freigesetzten rekombinanten aav-vektoren
|
US6440944B2
(en)
|
1998-10-16 |
2002-08-27 |
Genvec, Inc. |
Methods of administering adenoviral vectors
|
US6225289B1
(en)
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
EP1198559A1
(de)
*
|
1999-04-23 |
2002-04-24 |
Introgene B.V. |
Mittel und verfahren zum transport von nukleinsäuren
|
RU2245366C2
(ru)
|
1999-04-30 |
2005-01-27 |
Чирон С.Р.Л. |
Антиген neisseria, кодирующая его нуклеиновая кислота, их использование
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
FR2799472B1
(fr)
|
1999-10-07 |
2004-07-16 |
Aventis Pharma Sa |
Preparation d'adenovirus recombinants et de banques adenovirales
|
EP2275552B1
(de)
|
1999-10-29 |
2015-09-09 |
GlaxoSmithKline Biologicals SA |
Antigenpeptide aius Neisseria
|
PT2289545T
(pt)
|
2000-01-17 |
2016-09-06 |
Glaxosmithkline Biologicals Sa |
Vacina de omv suplementada contra meningococos
|
US6821775B1
(en)
*
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
US7653769B2
(en)
*
|
2006-12-14 |
2010-01-26 |
International Business Machines Corporation |
Management of devices connected to infiniband ports
|
US6591543B2
(en)
*
|
2000-04-14 |
2003-07-15 |
Kenneth P. Sabine |
Top water lure with highly active propeller
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US6579522B1
(en)
|
2000-06-27 |
2003-06-17 |
Genvec, Inc. |
Replication deficient adenoviral TNF vector
|
US6984522B2
(en)
*
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US6573092B1
(en)
|
2000-10-10 |
2003-06-03 |
Genvec, Inc. |
Method of preparing a eukaryotic viral vector
|
MXPA03003690A
(es)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
DE10108412B4
(de)
*
|
2001-02-21 |
2006-03-09 |
Cevec Pharmaceuticals Gmbh |
Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
EP1404842A2
(de)
*
|
2001-06-29 |
2004-04-07 |
Novartis AG |
Screeningverfahren für perv und dessen verwendung
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
WO2003022311A1
(en)
*
|
2001-09-13 |
2003-03-20 |
Genvec, Inc. |
Adenoviral vector and related system and methods of making and use
|
DE10150984A1
(de)
*
|
2001-10-16 |
2003-04-17 |
Holm Per Sonne |
Verwendung des adenoviralen E2-late-Promotors
|
US20030087438A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
E1-revertant-free adenoviral composition
|
US20030086903A1
(en)
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
ES2312649T3
(es)
|
2001-12-12 |
2009-03-01 |
Novartis Vaccines And Diagnostics S.R.L. |
Inmunizacion frente a chlamydia trachomatis.
|
JP2005532036A
(ja)
|
2002-01-09 |
2005-10-27 |
理化学研究所 |
癌プロフィール
|
AU2003210661A1
(en)
*
|
2002-01-24 |
2003-09-02 |
Novartis Ag |
Fiber shaft modifications for efficient targeting
|
WO2003070256A1
(en)
*
|
2002-02-15 |
2003-08-28 |
Research Development Foundation |
Hyaluronic acid mediated adenoviral transduction
|
US20030158112A1
(en)
*
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
US20060099178A1
(en)
|
2002-05-27 |
2006-05-11 |
Holm Per S |
Novel use of adenoviruses and nucleic acids coding therefor
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
CA2507036A1
(en)
*
|
2002-12-02 |
2004-06-17 |
Genvec, Inc. |
Materials and methods for treating ocular-related disorders
|
AU2003300076C1
(en)
|
2002-12-30 |
2010-03-04 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
US20080124360A1
(en)
|
2003-01-24 |
2008-05-29 |
Seggern Daniel J Von |
Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
|
US20040166091A1
(en)
*
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
WO2005017149A1
(en)
*
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
|
US7485291B2
(en)
*
|
2003-06-03 |
2009-02-03 |
Cell Genesys, Inc. |
Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
|
US7186699B2
(en)
*
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
AU2004256425A1
(en)
|
2003-06-09 |
2005-01-20 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
US7026164B2
(en)
|
2003-07-03 |
2006-04-11 |
Cell Genesys, Inc. |
Adenovirus packaging cell lines
|
ES2391975T3
(es)
*
|
2003-07-25 |
2012-12-03 |
Genvec, Inc. |
Vacunas a base de vector adenovírico
|
CN1863918B
(zh)
|
2003-10-02 |
2011-03-30 |
克鲁塞尔荷兰公司 |
用于重组腺病毒的包装细胞
|
ATE458500T1
(de)
*
|
2003-11-14 |
2010-03-15 |
Genvec Inc |
Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
|
US20070110719A1
(en)
|
2003-11-14 |
2007-05-17 |
Holm Per S |
Novel use of adenoviruses and nucleic acids that code for said viruses
|
EP1689446B1
(de)
*
|
2003-11-14 |
2015-01-07 |
Per Sonne Holm |
Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
|
EP1697534B1
(de)
|
2003-12-01 |
2010-06-02 |
Life Technologies Corporation |
Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
|
EP1718767B1
(de)
*
|
2004-02-03 |
2012-04-11 |
The Regents Of The University Of Michigan |
Zusammensetzungen zur behandlung von brust- und bauchspeicheldrüsenkrebs
|
AU2005214090B2
(en)
*
|
2004-02-23 |
2008-09-11 |
Crucell Holland B.V. |
Virus purification methods
|
WO2005089811A1
(en)
*
|
2004-03-12 |
2005-09-29 |
Genvec, Inc. |
Materials for treating vascular leakage in the eye
|
PT1736541E
(pt)
|
2004-03-29 |
2013-01-31 |
Galpharma Co Ltd |
Nova proteína galectina 9 modificada e sua utilização
|
MXPA06011553A
(es)
|
2004-04-05 |
2007-01-26 |
Univ California |
Modulacion de nkg2d.
|
JP2007532656A
(ja)
|
2004-04-12 |
2007-11-15 |
アメリカ合衆国 |
アデノウイルスベクターを用いて免疫応答を誘導するための方法
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
WO2006039045A2
(en)
*
|
2004-09-01 |
2006-04-13 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
US20060057127A1
(en)
*
|
2004-09-10 |
2006-03-16 |
Pocheng Liu |
Cytokine-expressing cellular vaccines for treatment of prostate cancer
|
EP1835929B8
(de)
|
2005-01-06 |
2016-07-27 |
Novo Nordisk A/S |
Behandlungen und verfahren mit anti-kir-kombination
|
US20060188481A1
(en)
*
|
2005-02-22 |
2006-08-24 |
Saitama Medical School |
Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
|
CN101155915B
(zh)
*
|
2005-04-11 |
2013-12-04 |
克鲁塞尔荷兰公司 |
利用超滤进行病毒纯化
|
US20060234347A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Harding Thomas C |
Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
|
US7825231B2
(en)
*
|
2005-06-01 |
2010-11-02 |
Darren P. Wolfe |
Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
|
WO2006130806A2
(en)
*
|
2005-06-01 |
2006-12-07 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Assay for agonists and antagonists of ion channels and for regulators of genetic expression
|
US20060292159A1
(en)
*
|
2005-06-08 |
2006-12-28 |
Ranscht Barbara E |
Methods for the inhibition of neovascularization and cancer metastasis
|
CA2612021A1
(en)
*
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
WO2006135886A2
(en)
*
|
2005-06-13 |
2006-12-21 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
EP1910550A4
(de)
|
2005-07-21 |
2009-11-04 |
Abbott Lab |
Expression mehrerer gene unter einschluss von sorf-konstrukten und verfahren mit polyproteinen, proproteinen und proteolyse
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
JP2009505680A
(ja)
|
2005-08-31 |
2009-02-12 |
ジェンベク、インコーポレイティッド |
アデノウイルスベクターに基づくマラリアワクチン
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
AU2006291054B2
(en)
|
2005-09-12 |
2011-10-13 |
The Brigham And Women's Hospital, Inc. |
Recurrent gene fusions in prostate cancer
|
US8652467B2
(en)
*
|
2005-10-14 |
2014-02-18 |
The Regents Of The University Of Michigan |
Dek protein compositions and methods of using the same
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
CA2628116A1
(en)
|
2005-10-31 |
2007-12-13 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
CA2628255C
(en)
*
|
2005-10-31 |
2016-04-19 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
EP1951297A2
(de)
|
2005-11-10 |
2008-08-06 |
GenVec, Inc. |
Adenoviraler vektorbasierter impfstoff für die maul- und klauen-seuche
|
WO2007062656A2
(en)
*
|
2005-11-30 |
2007-06-07 |
Copenhagen University |
A nucleotide vaccine
|
WO2007094653A1
(en)
*
|
2006-02-13 |
2007-08-23 |
Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg |
Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
|
US20110206692A1
(en)
|
2006-06-09 |
2011-08-25 |
Novartis Ag |
Conformers of bacterial adhesins
|
JP2009541333A
(ja)
*
|
2006-06-23 |
2009-11-26 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
修飾リボヌクレアーゼ
|
EP2049151A4
(de)
|
2006-07-17 |
2010-03-24 |
Quintessence Biosciences Inc |
Verfahren und zusammensetzungen zur behandlung von krebs
|
WO2008030605A2
(en)
*
|
2006-09-08 |
2008-03-13 |
The Regents Of The University Of Michigan |
Herv group ii viruses in lymphoma and cancer
|
HUE026600T2
(hu)
*
|
2006-12-01 |
2016-06-28 |
Hepc Terapia Kereskedelmi Es Szolgaltato Zartkoerueen Muekoedoe Reszvenytarsasag |
Készítmények és eljárások virális hepatitis kezelésére
|
EP2114445A2
(de)
*
|
2007-01-09 |
2009-11-11 |
Genvec, Inc. |
Auf adenoviralen vektoren basierende malaria-impfstoffe
|
EP2106439B1
(de)
|
2007-01-24 |
2014-11-12 |
The Regents of the University of Michigan |
Zusammensetzungen und verfahren zur behandlung und diagnostizierung von pankreaskrebs
|
EP2132300B1
(de)
*
|
2007-03-09 |
2011-01-12 |
Vectorlogics, Inc. |
Zellen für adenovirusvektor- und proteinherstellung
|
US20090324596A1
(en)
*
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
CA2692441C
(en)
|
2007-07-06 |
2020-01-21 |
The Regents Of The University Of Michigan |
Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
|
US20090047269A1
(en)
|
2007-08-16 |
2009-02-19 |
The Regents Of The University Of Michigan |
Metabolomic cancer targets
|
US8697062B2
(en)
*
|
2007-10-08 |
2014-04-15 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapeutics
|
EP2612868B1
(de)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunsuppressive Polypeptide und Nucleinsäuren
|
US20090202492A1
(en)
*
|
2008-01-25 |
2009-08-13 |
University Of South Florida |
Adenovirus vaccine utilizing ikk as adjuvant
|
US8193151B2
(en)
*
|
2008-04-25 |
2012-06-05 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias
|
US8518884B2
(en)
|
2008-04-25 |
2013-08-27 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
|
WO2010037041A2
(en)
|
2008-09-26 |
2010-04-01 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
EP2334695B1
(de)
|
2008-10-01 |
2015-12-23 |
Quintessence Biosciences, Inc. |
Therapeutische ribonukleasen
|
ES2532015T3
(es)
*
|
2008-11-03 |
2015-03-23 |
Crucell Holland B.V. |
Método para la producción de vectores adenovíricos
|
JP2012514475A
(ja)
|
2009-01-09 |
2012-06-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
癌における再現性の遺伝子融合物
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
CN102575233B
(zh)
|
2009-10-15 |
2014-07-16 |
克鲁塞尔荷兰公司 |
从高细胞密度培养物纯化腺病毒的方法
|
AU2010305765B2
(en)
|
2009-10-15 |
2015-07-02 |
Crucell Holland B.V. |
Method for the purification of adenovirus particles
|
WO2011047316A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
AU2010313395A1
(en)
|
2009-10-30 |
2012-05-10 |
Abbvie Inc. |
sORF constructs and multiple gene expression
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
JP5980117B2
(ja)
|
2009-11-09 |
2016-08-31 |
ジェンヴェック,インコーポレーテッド |
サルアデノウイルスベクターの増殖方法
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
WO2011098592A1
(en)
|
2010-02-15 |
2011-08-18 |
Crucell Holland B.V. |
Method for the production of ad26 adenoviral vectors
|
WO2011116209A2
(en)
*
|
2010-03-17 |
2011-09-22 |
The Regents Of The University Of Michigan |
Using phage epitopes to profile the immune response
|
ES2887335T3
(es)
|
2010-03-17 |
2021-12-22 |
Univ Cornell |
Vacuna contra las drogas de abuso basada en adenovirus alterado
|
TWI688395B
(zh)
|
2010-03-23 |
2020-03-21 |
英翠克頌公司 |
條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途
|
CA2794674A1
(en)
|
2010-04-01 |
2011-10-06 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
US8771709B2
(en)
|
2010-09-20 |
2014-07-08 |
Crucell Holland B.V. |
Therapeutic vaccination against active Tuberculosis
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
SG10201600912SA
(en)
|
2011-03-04 |
2016-03-30 |
Intrexon Corp |
Vectors conditionally expressing protein
|
WO2012162428A1
(en)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prime-boost vaccination for viral infection
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
US10980879B2
(en)
|
2011-07-06 |
2021-04-20 |
Sykehuset Sørlandet Hf |
EGFR targeted therapy
|
EP2764011B1
(de)
|
2011-10-05 |
2021-04-07 |
GenVec, Inc. |
Auf adenovirenvektoren-basierender impfstoff gegen das respiratorische synzytialvirus (rsv)
|
BR112014008284A2
(pt)
|
2011-10-05 |
2020-10-27 |
Genvec Inc. |
adenovirus (gorilla) simian ou vetores adenovirais e métodos de uso
|
US9233153B2
(en)
|
2011-10-05 |
2016-01-12 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
BR112014008249B1
(pt)
|
2011-10-05 |
2022-03-15 |
Genvec Inc |
Adenovírus ou vetor adenoviral e composição com os mesmos
|
DK2797613T3
(da)
|
2011-10-27 |
2020-03-02 |
Wellstat Ophthalmics Corp |
Vektorer, der koder for rod-derived cone viability-faktor
|
EP2780034A1
(de)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologe prime-boost-impfung mit auf masernviren basierten impfstoffen
|
US20150157700A1
(en)
|
2012-02-02 |
2015-06-11 |
GanVec, Inc. |
Adenoviral vector-based malaria vaccine
|
WO2013119880A1
(en)
|
2012-02-07 |
2013-08-15 |
Global Bio Therapeutics Usa, Inc. |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
CN104379733B
(zh)
|
2012-03-12 |
2016-01-20 |
克鲁塞尔荷兰公司 |
具改变末端的重组腺病毒群
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
MY169352A
(en)
|
2012-03-22 |
2019-03-25 |
Janssen Vaccines & Prevention Bv |
Vaccine against rsv
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
EP2855669B1
(de)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Modifizierte serotyp-28-adenovirusvektoren
|
US9676824B2
(en)
|
2012-05-29 |
2017-06-13 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
ES2752190T3
(es)
|
2012-09-14 |
2020-04-03 |
Us Health |
Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
|
WO2014066328A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
AU2013362134B2
(en)
|
2012-12-21 |
2018-07-05 |
Sykehuset Sorlandet Hf |
EGFR targeted therapy of neurological disorders and pain
|
JP2016510411A
(ja)
|
2013-02-04 |
2016-04-07 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Wnt経路インヒビターによる処置の方法およびモニタリング
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
DE102013004595A1
(de)
|
2013-03-15 |
2014-09-18 |
Emergent Product Development Germany Gmbh |
RSV-Impfstoffe
|
MX361774B
(es)
|
2013-04-25 |
2018-12-17 |
Janssen Vaccines & Prevention Bv |
Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados.
|
PE20160045A1
(es)
|
2013-06-17 |
2016-02-18 |
Crucell Holland Bv |
Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
|
US11364032B2
(en)
|
2013-08-08 |
2022-06-21 |
Global Bio Therapeutics, Inc. |
Clamp device for minimally invasive procedures and uses thereof
|
PL3046536T3
(pl)
|
2013-09-19 |
2019-06-28 |
Janssen Vaccines & Prevention B.V. |
Ulepszone formulacje adenowirusów
|
WO2016037154A1
(en)
|
2014-09-04 |
2016-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant hiv-1 envelope proteins and their use
|
CA2957800A1
(en)
|
2014-09-07 |
2016-03-10 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector immune responses
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
CN107075521B
(zh)
|
2014-11-04 |
2021-06-08 |
扬森疫苗与预防公司 |
治疗性hpv16疫苗
|
EP3236998A1
(de)
|
2014-12-24 |
2017-11-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Rekombinante metapneumovirusproteine und deren verwendung
|
JP7020917B2
(ja)
|
2015-01-20 |
2022-02-16 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
キメラrsv/bpiv3 fタンパクを発現する組換えヒト/ウシパラインフルエンザウイルス3(b/hpiv3)およびその使用
|
EP3261665A1
(de)
|
2015-02-24 |
2018-01-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Mers-coronavirusimmunogene, antikörper und deren verwendung
|
DK3271729T3
(da)
|
2015-03-18 |
2020-12-14 |
Janssen Vaccines & Prevention Bv |
Analyser til rekombinante ekspressionssystemer
|
US10570417B2
(en)
|
2015-04-14 |
2020-02-25 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
JP6840718B2
(ja)
|
2015-07-07 |
2021-03-10 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化された可溶性融合前rsv fポリペプチド
|
WO2017005844A1
(en)
|
2015-07-07 |
2017-01-12 |
Janssen Vaccines & Prevention B.V. |
Vaccine against rsv
|
CN108289940B
(zh)
|
2015-08-03 |
2023-01-13 |
美国卫生和人力服务部 |
Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途
|
EA037295B1
(ru)
|
2015-08-20 |
2021-03-05 |
Янссен Вэксинс Энд Превеншн Б.В. |
Терапевтические вакцины против hpv18
|
ES2907486T3
(es)
|
2015-09-24 |
2022-04-25 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para reducir metástasis
|
EP3359132B1
(de)
|
2015-10-06 |
2023-08-16 |
Janssen Vaccines & Prevention B.V. |
Verfahren zur konservierung von biologischen produkten in kunststoffbehältern
|
US10377801B2
(en)
|
2015-11-04 |
2019-08-13 |
Northwestern University |
Amelioration of chronic kidney disease
|
WO2017139392A1
(en)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
WO2017156272A1
(en)
|
2016-03-09 |
2017-09-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
BR112018070323A2
(pt)
|
2016-04-05 |
2019-01-29 |
Janssen Vaccines & Prevention Bv |
vacina contra rsv
|
AU2017248021B2
(en)
|
2016-04-05 |
2021-08-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F proteins
|
AU2017259259B2
(en)
|
2016-05-02 |
2020-11-19 |
Bavarian Nordic A/S |
Therapeutic HPV vaccine combinations
|
RU2758238C2
(ru)
|
2016-05-12 |
2021-10-26 |
Янссен Вэксинс Энд Превеншн Б.В. |
Эффективный и сбалансированный двунаправленный промотор
|
WO2017207480A1
(en)
|
2016-05-30 |
2017-12-07 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv f proteins
|
US11001858B2
(en)
|
2016-06-20 |
2021-05-11 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
WO2018013509A1
(en)
|
2016-07-11 |
2018-01-18 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for diagnosing and treating arrhythmias
|
WO2018011196A1
(en)
|
2016-07-14 |
2018-01-18 |
Janssen Vaccines & Prevention B.V. |
Hpv vaccines
|
CA3038968A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
US11602559B2
(en)
|
2016-10-03 |
2023-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV-1 Env fusion peptide immunogens and their use
|
EP3522920A2
(de)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
|
EP3532095A1
(de)
|
2016-10-25 |
2019-09-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Präfusionscoronavirus-spike-proteine und deren verwendung
|
EP3329930A1
(de)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Pharmazeutische zusammensetzungen
|
EP3548058B1
(de)
|
2016-12-05 |
2022-06-22 |
Nuritas Limited |
Zusammensetzungen enthaltend peptid wkdeagkplvk
|
MX2019006349A
(es)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
|
KR20190104194A
(ko)
|
2017-01-07 |
2019-09-06 |
셀렉타 바이오사이언시즈, 인크. |
합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
|
US11241436B2
(en)
|
2017-01-25 |
2022-02-08 |
Northwestern University |
Autophagy inducers for treatment of CNS conditions
|
KR102111244B1
(ko)
|
2017-02-09 |
2020-05-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
이종 유전자의 발현을 위한 강력한 짧은 프로모터
|
US11235056B2
(en)
|
2017-03-24 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of HIV-1 gp120 and their use
|
EP3624844A1
(de)
|
2017-05-17 |
2020-03-25 |
Janssen Vaccines & Prevention B.V. |
Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen
|
EP3681533A1
(de)
|
2017-09-15 |
2020-07-22 |
Janssen Vaccines & Prevention B.V. |
Verfahren zur sicheren induktion der immunität gegen rsv
|
BR112020007157A2
(pt)
|
2017-10-13 |
2020-09-24 |
Selecta Biosciences, Inc. |
métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
|
US11136356B2
(en)
|
2017-10-16 |
2021-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
WO2019086450A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
SG11202003290RA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof
|
SG11202003398SA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus vectors and uses thereof
|
US11142551B2
(en)
|
2017-10-31 |
2021-10-12 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
AU2018372906A1
(en)
|
2017-11-22 |
2020-06-11 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cancer
|
SG11202006399VA
(en)
|
2018-01-23 |
2020-08-28 |
Janssen Vaccines & Prevention Bv |
Influenza virus vaccines and uses thereof
|
AU2019231652A1
(en)
|
2018-03-06 |
2020-10-01 |
Precigen, Inc. |
Hepatitis B vaccines and uses of the same
|
AU2019368218A1
(en)
|
2018-10-22 |
2021-05-27 |
New York University |
Recombinant GP120 protein with V1-loop deletion
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
***新抗原及其用途
|
MX2021012991A
(es)
|
2019-04-25 |
2021-12-10 |
Janssen Vaccines & Prevention Bv |
Antigenos de gripe recombinantes.
|
CA3138525A1
(en)
|
2019-04-28 |
2020-11-05 |
Selecta Biosciences, Inc. |
Methods for treatment of subjects with preexisting immunity to viral transfer vectors
|
US20220273787A1
(en)
|
2019-05-15 |
2022-09-01 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
CA3140234A1
(en)
|
2019-05-15 |
2020-11-19 |
Janssen Vaccines & Prevention B.V. |
Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
|
EP3976802A1
(de)
|
2019-05-28 |
2022-04-06 |
Selecta Biosciences, Inc. |
Verfahren und zusammensetzungen für abgeschwächte immunantwort auf antivirale transfervektoren
|
WO2021028837A1
(en)
|
2019-08-13 |
2021-02-18 |
Waters Technologies Corporation |
Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains
|
CN114430742A
(zh)
|
2019-09-05 |
2022-05-03 |
扬森疫苗与预防公司 |
流感病毒疫苗及其用途
|
IL291852A
(en)
|
2019-10-03 |
2022-06-01 |
Janssen Vaccines & Prevention Bv |
Adenovirus vectors and their use
|
AU2020361533A1
(en)
|
2019-10-08 |
2022-04-28 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
AU2020385683A1
(en)
|
2019-11-18 |
2022-06-30 |
Janssen Biotech, Inc. |
Vaccines based on mutant CALR and JAK2 and their uses
|
EP4103229A1
(de)
|
2020-02-11 |
2022-12-21 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Sars-cov-2-impfstoff
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
CA3170369A1
(en)
|
2020-03-05 |
2022-04-14 |
Michal Shahar |
Methods and compositions for treating cancer with immune cells
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
JP2023521194A
(ja)
|
2020-04-13 |
2023-05-23 |
ヤンセン バイオテツク,インコーポレーテツド |
Psma及びsteap1ワクチン並びにそれらの使用
|
EP4142785A2
(de)
|
2020-04-29 |
2023-03-08 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Rekombinante menschliche metapneumovirus f proteine und deren verwendung
|
EP4175664A2
(de)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostata-neoantigene und ihre verwendungen
|
US20230024133A1
(en)
|
2020-07-06 |
2023-01-26 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
WO2022035860A2
(en)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Replication-competent adenovirus type 4-hiv env vaccines and their use
|
JP2023537818A
(ja)
|
2020-08-11 |
2023-09-06 |
マスキュロスケレタル トランスプラント ファウンデーション |
胎盤由来組成物を用いた心疾患を治療するための方法
|
WO2022232648A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion-stabilized lassa virus glycoprotein complex and its use
|
EP4380613A1
(de)
|
2021-08-03 |
2024-06-12 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Hiv-1 impfung und samt-247 microbizid zur vorbeugung von hiv-1 infektion
|
CN118139655A
(zh)
|
2021-08-13 |
2024-06-04 |
特里奥万斯控股公司 |
皮肤替代组合物及其产生和使用方法
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
WO2023091696A1
(en)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Adenovirus delivery system for cancer treatment
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
WO2023192835A1
(en)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Base-covered hiv-1 envelope ectodomains and their use
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
EP4338727A1
(de)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus-formulierungen
|